๐ฐ Leukemia News
Page 96 - Leukemia News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Leukemia. Real-time updates on events, politics, business and more.
October 12, 2023
Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.
October 11, 2023
We are just three nights away from the fundraiser that draws one of the biggest crowds in the Capital Region.
October 10, 2023
A new, bio-inspired drug restores the effectiveness of immune cells in fighting cancer, a team led by researchers at The University of Texas at Austin has found.
October 10, 2023
Sarah Wall, MD, talks about how itโs important to consider patient age when treating older patients with cancer because it will impact so many of them and blood cancers act differently and can be more aggressive in older adults.
October 10, 2023
Struggles with housing and food security as well as concerns about medication side effects appear to exacerbate a lack of medication adherence.
October 9, 2023
Patients with chronic lymphocytic leukemia who experience disease progression during treatment with either covalent or noncovalent BTK inhibitors displayed a higher frequency of BTK mutations in L528W as well as RAS/RAF/MAPK pathway alterations, indicating that these alterations may play a role in the development of BTK inhibitor resistance.
October 9, 2023
Understanding the complex interplay between diet, gut microbiota, and leukemia is a critical aspect of leukemia prevention and treatment. TheHealthSite.com
October 9, 2023
The undetectable minimal residual disease ate achieved with bendamustine followed by obinutuzumab, acalabrutinib, and venetoclax increased as the regimen was continued as maintenance treatment in patients with relapsed or refractory chronic lymphocytic leukemia.
October 9, 2023
Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.